UnknownNot Applicable

PET Imaging of Fibroblast Activation in Atherosclerosis

China150 participantsStarted 2021-08-01

Plain-language summary

Fibroblast activation protein (FAP) is a fibroblast-specific marker expressed in atherosclerosis, associated with endothelial-to-mesenchymal transition and a rupture-prone plaque phenotype. This study aims to evaluate in-vivo fibroblast activation in carotid and coronary atherosclerotic diseases with FAPI PET and its correlation with histological vulnerability and clinical outcome.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * For the carotid stenosis group: patients with symptomatic carotid stenosis with \>50% stenosis on carotid CTA; OR patients with unsymptomatic carotid stenosis with \>70% stenosis on carotid CTA * For CAD group: patients with stable ischemic heart disease OR acute coronary syndrome, including ST-elevation MId, non-ST elevation MI, and unstable angina * signed informed consent Exclusion Criteria: * Pregnancy, lactation, or intention to become pregnant during the study * Contradiction to MRI or CTA

What they're measuring

SUVmax of atherosclerotic plaque in carotid or coronary arteries

Timeframe: through study completion, an average of 2 years

TBR of atherosclerotic plaque in carotid or coronary arteries

Timeframe: through study completion, an average of 2 years

Trial details

NCT IDNCT06280287

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

Contact for this trial

Li Huo

+861069155513 huoli@pumch.cn

View on ClinicalTrials.gov More Atherosclerosis trials